Blinatumomab + olverembatinib
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Phase II Clinical Trial
Conditions
Phase II Clinical Trial, Blinatumomab, Olverembatinib, Lymphoblastic Leukemia, Philadelphia Chromosome Positive
Trial Timeline
Aug 27, 2026 → Sep 30, 2033
NCT ID
NCT07178912About Blinatumomab + olverembatinib
Blinatumomab + olverembatinib is a phase 2 stage product being developed by Amgen for Phase II Clinical Trial. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07178912. Target conditions include Phase II Clinical Trial, Blinatumomab, Olverembatinib.
What happened to similar drugs?
7 of 15 similar drugs in Phase II Clinical Trial were approved
Approved (7) Terminated (2) Active (6)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07178912 | Phase 2 | Recruiting |
Competing Products
20 competing products in Phase II Clinical Trial
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TERN-701 | Terns Pharmaceuticals | Phase 1/2 | 36 |
| Tamsulosin HCl + Solifenacin Succinate + EC905 | Astellas Pharma | Phase 1 | 29 |
| solifenacin succinate + mirabegron + mirabegron/solifenacin succinate | Astellas Pharma | Phase 1 | 29 |
| Graceptor® | Astellas Pharma | Pre-clinical | 26 |
| Lemborexant + Placebo | Eisai | Approved | 50 |
| BIW-8962 | Kyowa Kirin | Phase 1/2 | 24 |
| Acalabrutinib | AstraZeneca | Phase 1/2 | 36 |
| Sacituzumab tirumotecan | Merck | Phase 2 | 42 |
| progesterone + Progesterone | Merck | Approved | 39 |
| Asciminib | Novartis | Pre-clinical | 30 |
| Nilotinib | Novartis | Phase 3 | 40 |
| Imatinib mesylate | Novartis | Phase 3 | 32 |
| Imatinib Mesylate 600 MG Oral Tablet + Imatinib Mesylate 400 MG Oral Tablet + Imatinib Mesylate | Novartis | Phase 3 | 32 |
| ribociclib + Trametinib | Novartis | Phase 1 | 21 |
| Nilotinib | Novartis | Approved | 43 |
| Imatinib | Novartis | Phase 3 | 40 |
| Nilotinib | Novartis | Approved | 43 |
| Gleevec | Novartis | Phase 2 | 35 |
| Nilotinib + Ruxolitinib | Novartis | Phase 1/2 | 32 |
| ABL001 | Novartis | Phase 3 | 40 |